Overview

• The investor-oriented analysis singles out a single drugmaker as the standout dividend stock to buy with $1,000 right now.
• Shares of Pfizer are reported to be about 60% below recent highs, with Merck and Bristol Myers Squibb down roughly 40%, lifting dividend yields.
• The piece cites a more negative mood in Washington toward the drug industry, with vaccine makers feeling particular pressure.
• It notes that patent cliffs are a routine industry challenge that can trigger material sales declines when generics enter.
• At least one company highlighted is credited with a long history of maintaining its dividend through difficult periods.